Buchumschlag

Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial

Background - The CAO/ARO/AIO trial has shown that oxaliplatin added to preoperative chemoradiotherapy and postoperative chemotherapy significantly improved disease-free survival in locally advanced rectal cancer (LARC). Here, we present a post-hoc analysis of quality of life (QoL) in disease-free pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kosmala, Rebekka (VerfasserIn) , Fokas, Emmanouil (VerfasserIn) , Flentje, Michael (VerfasserIn) , Sauer, Rolf (VerfasserIn) , Liersch, Torsten (VerfasserIn) , Graeven, Ullrich (VerfasserIn) , Fietkau, Rainer (VerfasserIn) , Hohenberger, Werner (VerfasserIn) , Arnold, Dirk (VerfasserIn) , Hofheinz, Ralf-Dieter (VerfasserIn) , Ghadimi, Michael (VerfasserIn) , Ströbel, Philipp (VerfasserIn) , Staib, Ludger (VerfasserIn) , Grabenbauer, Gerhard G. (VerfasserIn) , Folprecht, Gunnar (VerfasserIn) , Kirste, Simon (VerfasserIn) , Uter, Wolfgang (VerfasserIn) , Gall, Christine (VerfasserIn) , Rödel, Claus (VerfasserIn) , Polat, Bülent (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: February 2021
In: European journal of cancer
Year: 2021, Jahrgang: 144, Pages: 281-290
ISSN:1879-0852
DOI:10.1016/j.ejca.2020.11.029
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ejca.2020.11.029
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804920313666
Volltext
Verfasserangaben:Rebekka Kosmala, Emmanouil Fokas, Michael Flentje, Rolf Sauer, Torsten Liersch, Ullrich Graeven, Rainer Fietkau, Werner Hohenberger, Dirk Arnold, Ralf-Dieter Hofheinz, Michael Ghadimi, Philipp Ströbel, Ludger Staib, Gerhard G. Grabenbauer, Gunnar Folprecht, Simon Kirste, Wolfgang Uter, Christine Gall, Claus Rödel, Bülent Polat
Beschreibung
Zusammenfassung:Background - The CAO/ARO/AIO trial has shown that oxaliplatin added to preoperative chemoradiotherapy and postoperative chemotherapy significantly improved disease-free survival in locally advanced rectal cancer (LARC). Here, we present a post-hoc analysis of quality of life (QoL) in disease-free patients. - Patients and methods - Between 2006 and 2010, 1236 patients with LARC were randomly assigned either to preoperative chemoradiotherapy followed by total mesorectal excision and postoperative chemotherapy (N = 623) or combined with oxaliplatin (N = 613). QoL questionnaires (EORTC QLQ-C30, colorectal module CR38) were completed at baseline, after postoperative chemotherapy and during follow-up. Analysis was performed according intent-to-treat. - Results - Available questionnaires (baseline) were 82% (N = 512) in the control and 84% (N = 513) in the investigational group. Response rates were 49% (533 of 1086) at 1 year and 43% (403 of 928) at 3 years. Global health status (GHS) for disease-free patients was stable in both groups (range 0-100). At baseline: standard arm 62.0 (mean, SD 21.6; N = 491) versus oxaliplatin arm 63.2 (mean, SD 22; N = 503); at 3 years: 69.4 (SD 19.3; N = 187) versus 65.4 (SD 22.2; N = 202). After treatment and at 3 years, no significant differences (≥10 points) between groups were found in QoL subscales. Disease-free patients experiencing neurotoxic side-effects (grade 1-4) showed reduced GHS at 3 years versus patients without neurotoxicity (mean 59.2 versus 69.3; P < 0.001), while grade 3-4 rate was low. - Conclusion - The addition of oxaliplatin was not associated with worse overall QoL. This information is of interest to patients in many ongoing rectal cancer trials. - Trial registration information - NCT00349076.
Beschreibung:Gesehen am 14.04.2021
Beschreibung:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2020.11.029

Ähnliche Einträge